Helen Louise Collins
Chief Medical Officer at Enliven Therapeutics, Inc. (ELVN)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 21SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 2,91627,084 held (−10%) | $50.03 | $146K | -18.1% |
| Sep 21SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 1,84425,240 held (−7%) | $50.71 | $94K | -19.2% |
| Sep 21SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 24025,000 held (−1%) | $51.48 | $12K | -20.4% |
| Aug 19SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 3,90026,100 held (−13%) | $58.37 | $228K | -29.8% |
| Aug 19SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 1,10025,000 held (−4%) | $59.35 | $65K | -31.0% |
| Jul 21SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 23129,769 held (−1%) | $50.05 | $12K | -18.1% |
| Jul 21SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 45929,310 held (−2%) | $51.55 | $24K | -20.5% |
| Jul 21SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 2,06327,247 held (−7%) | $52.39 | $108K | -21.8% |
| Jul 21SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 2,18425,063 held (−8%) | $53.42 | $117K | -23.3% |
| Jul 21SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 6325,000 held (−0%) | $53.92 | $3K | -24.0% |
| Jun 22SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 1,26828,732 held (−4%) | $42.83 | $54K | -4.3% |
| Jun 22SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 2,59926,133 held (−9%) | $43.87 | $114K | -6.6% |
| Jun 22SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 1,13325,000 held (−4%) | $44.74 | $51K | -8.4% |
| May 20SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 3,47526,525 held (−12%) | $39.53 | $137K | +3.7% |
| May 20SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 1,30225,223 held (−5%) | $40.25 | $52K | +1.8% |
| May 20SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 22325,000 held (−1%) | $41.21 | $9K | -0.6% |
| Apr 21SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 14029,860 held (−0%) | $45.81 | $6K | -10.5% |
| Apr 21SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 2,41927,441 held (−8%) | $47.39 | $115K | -13.5% |
| Apr 21SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 2,44125,000 held (−9%) | $48.06 | $117K | -14.7% |
| Mar 27SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 40,00025,000 held (−62%) | $35.10 | $1.4M | +16.8% |
| Mar 19SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 5,00025,000 held (−17%) | $27.76 | $139K | +47.6% |
| Mar 11SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 29,87125,000 held (−54%) | $30.02 | $897K | +36.5% |
| Mar 11SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 10,12925,000 held (−29%) | $30.19 | $306K | +35.7% |
| Feb 19SEC | ELVNEnliven Therapeutics, Inc. | Sell Plan | 45,00025,000 held (−64%) | $26.17 | $1.2M | +56.6% |
- Sell
Chief Medical Officer Helen Louise Collins sold $146K of ELVN at $50.03 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Helen Louise Collins sold $94K of ELVN at $50.71 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Helen Louise Collins sold $12K of ELVN at $51.48 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Helen Louise Collins sold $228K of ELVN at $58.37 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Helen Louise Collins sold $65K of ELVN at $59.35 — pre-scheduled 10b5-1 plan sale.
- Sell
Chief Medical Officer Helen Louise Collins sold $12K of ELVN at $50.05 — pre-scheduled 10b5-1 plan sale.